Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free JBIO Stock Alerts

Jade Biosciences (JBIO) Competitors

Jade Biosciences logo
$21.34 +0.04 (+0.19%)
Closing price 07/14/2026 04:00 PM Eastern
Extended Trading
$21.31 -0.03 (-0.14%)
As of 07/14/2026 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

JBIO vs. DNLI, NAMS, TLX, CPRX, and RCUS

Should you buy Jade Biosciences stock or one of its competitors? MarketBeat compares Jade Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jade Biosciences include Denali Therapeutics (DNLI), NewAmsterdam Pharma (NAMS), Telix Pharmaceuticals (TLX), Catalyst Pharmaceuticals (CPRX), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.

How does Jade Biosciences compare to Denali Therapeutics?

Jade Biosciences (NASDAQ:JBIO) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Jade Biosciences' return on equity of -51.34% beat Denali Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Jade BiosciencesN/A -51.34% -47.32%
Denali Therapeutics N/A -52.20%-43.86%

Jade Biosciences presently has a consensus price target of $51.57, indicating a potential upside of 141.67%. Denali Therapeutics has a consensus price target of $34.75, indicating a potential upside of 53.42%. Given Jade Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Jade Biosciences is more favorable than Denali Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90
Denali Therapeutics
1 Sell rating(s)
2 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.81

In the previous week, Denali Therapeutics had 7 more articles in the media than Jade Biosciences. MarketBeat recorded 11 mentions for Denali Therapeutics and 4 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.32 beat Denali Therapeutics' score of 0.76 indicating that Jade Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jade Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Denali Therapeutics
2 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Jade Biosciences has higher earnings, but lower revenue than Denali Therapeutics. Jade Biosciences is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jade BiosciencesN/AN/A-$127.41M-$2.02N/A
Denali Therapeutics$330.53M10.88-$512.54M-$2.88N/A

92.9% of Denali Therapeutics shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Jade Biosciences has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Summary

Jade Biosciences beats Denali Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Jade Biosciences compare to NewAmsterdam Pharma?

Jade Biosciences (NASDAQ:JBIO) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Jade Biosciences has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Jade Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Jade BiosciencesN/A -51.34% -47.32%
NewAmsterdam Pharma -943.23%-26.49%-24.37%

Jade Biosciences has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jade BiosciencesN/AN/A-$127.41M-$2.02N/A
NewAmsterdam Pharma$22.50M172.96-$203.82M-$1.79N/A

Jade Biosciences has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market.

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Jade Biosciences and Jade Biosciences both had 4 articles in the media. Jade Biosciences' average media sentiment score of 1.32 beat NewAmsterdam Pharma's score of 1.01 indicating that Jade Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jade Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NewAmsterdam Pharma
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Jade Biosciences presently has a consensus price target of $51.57, indicating a potential upside of 141.67%. NewAmsterdam Pharma has a consensus price target of $49.00, indicating a potential upside of 47.19%. Given Jade Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Jade Biosciences is more favorable than NewAmsterdam Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90
NewAmsterdam Pharma
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83

Summary

Jade Biosciences beats NewAmsterdam Pharma on 9 of the 15 factors compared between the two stocks.

How does Jade Biosciences compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Jade Biosciences (NASDAQ:JBIO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Telix Pharmaceuticals has higher revenue and earnings than Jade Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telix Pharmaceuticals$803.79M4.65-$7.12MN/AN/A
Jade BiosciencesN/AN/A-$127.41M-$2.02N/A

In the previous week, Telix Pharmaceuticals had 2 more articles in the media than Jade Biosciences. MarketBeat recorded 6 mentions for Telix Pharmaceuticals and 4 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.32 beat Telix Pharmaceuticals' score of 0.54 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Telix Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Jade Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Telix Pharmaceuticals' return on equity of 0.00% beat Jade Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Telix PharmaceuticalsN/A N/A N/A
Jade Biosciences N/A -51.34%-47.32%

Telix Pharmaceuticals presently has a consensus target price of $21.00, indicating a potential upside of 90.56%. Jade Biosciences has a consensus target price of $51.57, indicating a potential upside of 141.67%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Jade Biosciences is more favorable than Telix Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Telix Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90

Telix Pharmaceuticals has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

Summary

Jade Biosciences beats Telix Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Jade Biosciences compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Jade Biosciences (NASDAQ:JBIO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Comparatively, 23.1% of Jade Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Jade Biosciences' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Jade Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Catalyst Pharmaceuticals37.08% 35.76% 31.31%
Jade Biosciences N/A -51.34%-47.32%

Catalyst Pharmaceuticals has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalyst Pharmaceuticals$588.99M6.55$214.33M$1.7418.10
Jade BiosciencesN/AN/A-$127.41M-$2.02N/A

Catalyst Pharmaceuticals currently has a consensus target price of $32.00, indicating a potential upside of 1.62%. Jade Biosciences has a consensus target price of $51.57, indicating a potential upside of 141.67%. Given Jade Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Jade Biosciences is more favorable than Catalyst Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalyst Pharmaceuticals
0 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
2.56
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90

In the previous week, Catalyst Pharmaceuticals had 1 more articles in the media than Jade Biosciences. MarketBeat recorded 5 mentions for Catalyst Pharmaceuticals and 4 mentions for Jade Biosciences. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat Jade Biosciences' score of 1.32 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Catalyst Pharmaceuticals
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Jade Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Catalyst Pharmaceuticals beats Jade Biosciences on 10 of the 15 factors compared between the two stocks.

How does Jade Biosciences compare to Arcus Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

Jade Biosciences has higher earnings, but lower revenue than Arcus Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jade BiosciencesN/AN/A-$127.41M-$2.02N/A
Arcus Biosciences$247M14.47-$353M-$3.18N/A

In the previous week, Arcus Biosciences had 5 more articles in the media than Jade Biosciences. MarketBeat recorded 9 mentions for Arcus Biosciences and 4 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.32 beat Arcus Biosciences' score of 0.45 indicating that Jade Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jade Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Arcus Biosciences
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Jade Biosciences has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Jade Biosciences presently has a consensus price target of $51.57, suggesting a potential upside of 141.67%. Arcus Biosciences has a consensus price target of $35.10, suggesting a potential upside of 23.47%. Given Jade Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Jade Biosciences is more favorable than Arcus Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90
Arcus Biosciences
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.58

92.9% of Arcus Biosciences shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Jade Biosciences has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Jade Biosciences' return on equity of -51.34% beat Arcus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Jade BiosciencesN/A -51.34% -47.32%
Arcus Biosciences -156.36%-68.97%-35.27%

Summary

Jade Biosciences beats Arcus Biosciences on 10 of the 16 factors compared between the two stocks.

Get Jade Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for JBIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JBIO vs. The Competition

Export
MetricJade BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.05B$3.68B$6.86B$12.44B
Dividend YieldN/A2.19%2.68%8.42%
P/E Ratio-10.5620.9827.0124.38
Price / SalesN/A311.10521.3391.92
Price / CashN/A143.6648.5959.36
Price / Book3.178.5410.956.33
Net Income-$127.41M$23.83M$3.59B$331.02M
7 Day Performance-5.28%-2.77%-1.45%-0.33%
1 Month Performance32.55%5.85%2.78%-1.29%
1 Year Performance148.72%52.15%28.53%21.30%

Jade Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JBIO
Jade Biosciences
2.4789 of 5 stars		$21.34
+0.2%		$51.57
+141.7%		+137.1%$1.05BN/AN/A20
DNLI
Denali Therapeutics
3.2757 of 5 stars		$25.83
-0.6%		$34.25
+32.6%		+54.2%$4.10BN/AN/A430
NAMS
NewAmsterdam Pharma
3.314 of 5 stars		$34.79
-1.1%		$49.00
+40.8%		+50.2%$4.07B$22.50MN/A4
TLX
Telix Pharmaceuticals
4.5737 of 5 stars		$11.87
+0.3%		$21.13
+78.0%		-29.2%$4.03B$803.79MN/A1,184
CPRX
Catalyst Pharmaceuticals
3.8732 of 5 stars		$31.45
+0.0%		$32.00
+1.7%		+45.7%$3.85B$588.99M18.0780

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:JBIO) was last updated on 7/15/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel